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Abstract
Hsa-miR-4520-2-3p: A Potential Modulator of COVID-related ACE2 
Molly Ruggles and Nipun Chopra, Ph.D.






Angiotensin-Converting Enzyme (ACE2) is a transmembrane enzyme 
located in cells in various tissues around the body. Its normal role is the 
conversion of Angiotensin II to Angiotensin 1-7 leading to vasodilation and 
a subsequent reduction in blood pressure via the 
renin-angiotensin-aldosterone system. ACE2 also plays a pivotal role in the 
infection of COVID-19 as it determines entry of virus into human cells. 
SARS-CoV-2 uses one of its four structural proteins, the spike (S) 
glycoprotein, to bind to the ACE2 receptor. This entry into the cell begins 
the process of infection and spread of the disease; because of the 
abundance of ACE2 throughout the body, coronaviruses can enter several 
different organs. This multi-cell-entry via ACE2 is why COVID-19 affects 
multiple organ systems in the human body. Currently, therapies targeting 
ACE2 expression are limited. MicroRNA (miRNA)s are short non-coding 
RNA that downregulate the expression of a variety of proteins, and 
therefore offer a mechanism by which to inhibit the expression of ACE2. 
MiRNAs can potentially downregulate ACE2 protein synthesis by binding 
to the mRNA of ACE2 at a seed sequence. This binding results in mRNA 
degradation or inhibition of translation. Thus, our goal was to identify 
miRNA that may potentially target and downregulate ACE2. TargetScan, 
DIANA-MicroT, and PicTar are three algorithms that predict miRNAs that 
can bind to the mRNA of ACE2 and downregulate its expression. 
Together, the prediction tools resulted in 57 shared human miRNAs that 
target ACE2. We then utilized self-defined parameters to narrow down our 
list and identified hsa-miR-4520-2-3p as our predicted miRNA to target 
ACE2. This miRNA will be experimentally verified in the future.
Evidence suggests SARS-CoV-2 originated from bats, and it can be transmitted by 
human-to-human contact, through aerosols or large respiratory droplets. People 
being affected by SARS-CoV-2 may be experiencing a range of symptoms including 
fever, cough, myalgia, shortness of breath, hypoxemia, and acute respiratory distress 
syndrome. However, people who are positive for COVID-19 may also be 
asymptomatic, which makes viral spread more effective. Incubation period of 
SARS-CoV-2 is between 2-14 days.  
Figure 3. Workflow for research project.
Based on our in silico methodology, hsa-miR-4520-2-3p was narrowed as a 
potential miRNA targeting ACE2. This finding was based on a complete literature 
review, production of a list of miRNAs that target ACE2 by the three algorithms 
TargetScan, DIANA-MicroT, and PicTar, and self-defined parameters that further 
narrowed down the list of miRNAs predicted to target ACE2. 
A)
B)
Figure 5. A) SARS-CoV-2 utilizes S-protein binding to ACE2 protein to facilitate entry into the 
cell in absence of miRNA. B) Presence of miRNA eliminates ACE2, preventing SARS-CoV-2 
from gaining entry into the cell.
However, finding a miRNA that can suppress ACE2 is quite difficult. This is due to 
the reason that each miRNA is not exclusively bound to a specific mRNA. Thus, 
while the results were consistent with each other and allowed for the finding of one 
miRNA that could potentially target ACE2 in an experimental setting, 
hsa-miR-4520-2-3p could be a false positive when experimentally tested. 
Other limitations within this research were:
• The algorithms used limited results of the study, resulting in the possibility of 
both Type I and Type II errors.
• The parameters defined by the researchers within this experiment were limiting 
• The composition of miRNA has a short target sequence, hindering easy 
transfection of miRNA into cells for treatment of SARS-CoV-2
Figure 1. On March 12th, 2020, only three months after the first cases of the coronavirus 
disease 2019 (COVID19)--caused by SARS-CoV-2--were discovered in Wuhan, China, the 
disease was declared a pandemic by the WHO. As of September 29th, there have been over 
33.3 million confirmed cases of COVID-19 and about 1 million deaths across 188 countries, 
according to John Hopkins University.  
 
Figure 2. SARS-CoV-2 has a diameter of 150 nanometers and is made up of four structural 
proteins. One of those four proteins, the spike (S) glycoprotein on SARS-CoV-2 binds to the 
ACE2 protein. The virus then enters the cell via endocytosis. This image is from the CDC.
The main role of ACE2 is the conversion of Angiotensin II to Angiotensin 1-7, 
which opposes the actions of Angiotensin II. Angiotensin II is a peptide hormone 
that causes vasoconstriction, increased blood pressure, and sodium retention. 
Angiotensin 1-7 is a peptide, with one less amino acid than Angiotensin II, that 
causes vasodilation and decreased blood pressure. Thus, the normal function of 
ACE2 is important to maintain homeostasis in the human body. ACE2 is prevalent 
in many tissues throughout the body, including the lungs, esophagus, stratified 
epithelial cells, parts of the large intestine, and the brain; in fact ACE2 is capable 
or reducing levels of β-amyloid (Aβ) – a protein involved in the pathogenesis of 
Alzheimer’s disease (AD). The expression of ACE2 throughout the body is what 
can lead to multi-tissue infection when binding with SARS-CoV-2. 
MicroRNAs (miRNA) offer a novel approach for ACE2 inhibition. MiRNAs are 
~22 nucleotide, single-stranded, non-coding RNAs that regulate gene expression 
by binding to the messenger RNA (mRNA) of a protein at the miRNA seed 
sequence (Agarwal 2015). A seed sequence is a region of 2-8 nucleotides on the 
miRNA that is complementary to the within the 3’ untranslated region (UTR) 
within the mRNA. After miRNA binds to mRNA, the RNA-induced silencing 
complex (RISC) interferes with translation of ACE2 mRNA, resulting in either 
mRNA degradation or inhibition of ACE2 translation. Interference of translation 
allows miRNAs to downregulate ACE2 protein expression in order to decrease the 
number of opportunities available for the virus to infect a cell. 
Table 1. Above is a table showing a list of 20 miRNAs (narrowed down from the original 57) that 
are predicted to target ACE2. The miRNAs are ranked from the highest context++ score percentile to 
lowest. The table shows the specific scores assigned to these miRNA from TargetScan, 
DIANA-MicroT, and PicTar, yellow, blue, and orange, respectively.
Separately, TargetScan, DIANA-MicroT, and PicTar algorithms resulted in 281, 60, 
and one miRNA(s) predicted to target the ACE2 protein, respectively. 57 miRNAs 
were shared across the algorithms as potential targets for ACE2. 56 of the predicted 
miRNAs were shared among TargetScan and DIANA-MicroT, and one miRNA, 
miR-200c-3p was shared among all 3 algorithms.
Table 2. List of 20 miRNAs (narrowed down from the original 57) that are predicted to target 
ACE2. The varying shades of red indicate when a group of miRNAs are eliminated from being the 
sole miRNA (determined by the self-defined parameters) to target ACE2.  The darkest red indicates 
the first level of elimination, while the lightest red indicates the last level of elimination. The 
miRNAs are ranked from the highest miTG score to the lowest across each group. The miRNA 
highlighted in green is the determined miRNA that targets ACE2.
Figure 4. Filtered list of miRNA that potentially target ACE2. If there was experimental 
evidence on PubMed relating that a miRNA downregulated ACE2, then that miRNA was 
confirmed. If there were articles about ACE2 linked to the miRNA but no direct relationship, 
then that miRNA was unconfirmed. 
MiRNA Finalized by Parameters and Ranked by miTG Score
       MiRNA Ranked by Context++ Score Percentile
Future Research
Experimental research with the determined hsa-miR-4520-2-3p in order to 
determine if the miRNA does indeed target ACE2. Results of this future experiment 
could support or eliminate this miRNA as a potential regulator of ACE2.
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